Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial

被引：0
|
作者：
Qiuling Zhao
Ruixiang Xie
Wanfu Zhong
Wenbin Liu
Ting Chen
Xiuliang Qiu
Lin Yang
机构：
[1] Clinical Oncology School of Fujian Medical University,Department of Pharmacy
[2] Fujian Cancer Hospital,Department of Pharmacy
[3] Fujian University of Traditional Chinese Medicine,undefined
来源：
Cost Effectiveness and Resource Allocation | / 21卷
关键词：
Durvalumab; PD-L1; Biliary tract cancer; First-line treatment; Cost-effectiveness analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Chemotherapy with gemcitabine as first-line treatment for advanced biliary tract carcinoma
    Giacobino, A.
    Satolli, M. A.
    Dongiovanni, D.
    Rahimi, F.
    Milanesi, E.
    Zanini, M.
    Scigliano, M. C.
    Monge, T.
    Ceccarelli, M.
    Novarino, A.
    Ciorba, A.
    Manazza, A.
    Bertetto, O.
    Ciuffreda, L.
    ANNALS OF ONCOLOGY, 2007, 18 : 16 - 16
  • [22] FIRST-LINE CHEMOTHERAPY IN ADVANCED BILIARY TRACT CANCER: AN AUSTRALIAN EXPERIENCE
    Brungs, D.
    Aghmesheh, M.
    Sjoquist, K.
    Goldstein, D.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 51 - 51
  • [23] Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
    Wu, Meiyu
    Qin, Shuxia
    Wang, Liting
    Tan, Chongqing
    Peng, Ye
    Zeng, Xiaohui
    Luo, Xia
    Yi, Lidan
    Wan, Xiaomin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [24] Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China
    Li, Wei
    Wan, Li
    BMJ OPEN, 2023, 13 (09):
  • [25] Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
    Shao, Taihang
    Ren, Yinan
    Zhao, Mingye
    Tang, Wenxi
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [26] Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC
    Li, Jiahao
    Zhang, Tiantian
    Xu, Yongmei
    Lu, Peiyao
    Zhu, Jiaxin
    Liang, Wenhua
    Jiang, Jie
    IMMUNOTHERAPY, 2020, 12 (14) : 1067 - 1075
  • [27] Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer
    Finkelmeier, Fabian
    Bouattour, Mohamed
    Valle, Juan
    Vogel, Arndt
    Kim, Jin Won
    Kitano, Masayuki
    Chen, Jen-Shi
    Burris, Howard
    Zaucha, Renata
    Qin, Shukui
    Evesque, Ludovic
    Zhen, David B.
    Gupta, Vineet Govinda
    Park, Joon Oh
    Zotkiewicz, Magdalena
    Rokutanda, Nana
    Cohen, Gordon
    Oh, Do-Youn
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 63 - 64
  • [28] First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis
    Cao, Xueqiong
    Cai, Hongfu
    Li, Na
    Zheng, Bin
    Zheng, Zhiwei
    Liu, Maobai
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [29] Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer
    Zhang, Jiahao
    Lei, Jianying
    You, Caicong
    Fu, Wu
    Zheng, Bin
    Cai, Hongfu
    Liu, Maobai
    Li, Na
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [30] First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis
    Zheng, Zhiwei
    Fang, Ling
    Cai, Hongfu
    BMJ OPEN, 2023, 13 (12):
12345